Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMVT6Y3)

Drug Name
AP-24163 Drug Info
Synonyms
AP-24163; CHEMBL539433; 926922-16-9; 3-{(E)-2-[6-(Cyclopropylamino)-9h-Purin-9-Yl]ethenyl}-4-Methyl-N-[3-(4-Methyl-1h-Imidazol-1-Yl)-5-(Trifluoromethyl)phenyl]benzamide; Benzamide,3-[(1E)-2-[6-(cyclopropylamino)-9H-purin-9-yl]ethenyl]-4-methyl-N-[3-(4-methyl-1H-imidazol-1-yl)-5-(trifluoromethyl)phenyl]-; 3kfa; SCHEMBL4129401; SCHEMBL4129397; ZINC42919869; BDBM50294011; AP24163; KB-74929; 3-(2-(6-(cyclopropylamino)-9H-purin-9-yl)vinyl)-4-methyl-N-(3-(4-methyl-1H-imidazol-1-yl)-5-(trifluoromethyl)phenyl)benzamide
Indication
Disease Entry ICD 11 Status REF
Discovery agent N.A. Investigative [1]
Cross-matching ID
PubChem CID
44517649
TTD Drug ID
DMVT6Y3

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Patented Agent(s)
Approved Drug(s)
Clinical Trial Drug(s)
Download the Complete Related Drug List
Drug(s) Targeting Fusion protein Bcr-Abl T315I mutant (Bcr-Abl T315I)
Drug Name Drug ID Indication ICD 11 Highest Status REF
PMID25656651-Compound-37b DMX98YV N. A. N. A. Patented [3]
PMID25656651-Compound-36a DMNXVY9 N. A. N. A. Patented [3]
PMID25656651-Compound-37c DM684IK N. A. N. A. Patented [3]
PMID25656651-Compound-36d DMKMY4I N. A. N. A. Patented [3]
PMID25656651-Compound-36b DMHYDM7 N. A. N. A. Patented [3]
PMID25656651-Compound-36c DMOGKSW N. A. N. A. Patented [3]
PMID25656651-Compound-19b DMI1Z7D N. A. N. A. Patented [3]
PMID25656651-Compound-37a DM0P4F3 N. A. N. A. Patented [3]
PMID25656651-Compound-19a DMSNUVZ N. A. N. A. Patented [3]
Indazole derivative 5 DMM1I8R N. A. N. A. Patented [3]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Targeting Proto-oncogene c-Src (SRC)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Dasatinib DMJV2EK Blast phase chronic myelogenous leukemia, BCR-ABL1 positive Approved [4]
Bosutinib DMTI8YE Blast phase chronic myelogenous leukemia, BCR-ABL1 positive Approved [4]
SKI-758 DMQ8E9R Ischemia 8B10-8B11 Approved [5]
Herbimycin A DM6YWBF Solid tumour/cancer 2A00-2F9Z Approved [6]
AL3818 DM3WP0N Alveolar soft part sarcoma 2A60-2C35 Phase 3 [7]
CP-868596 DMZIM37 Gastrointestinal cancer 2C11 Phase 3 [7]
Masitinib DMRSNEU Amyotrophic lateral sclerosis 8B60.0 Phase 3 [8]
KX-01 DMF0NA9 Actinic keratosis EK90.0 Phase 3 [9]
Saracatinib DMBLHGP Hematologic tumour 2B33.Y Phase 2 [10]
TPX-0046 DMIVE67 Solid tumour/cancer 2A00-2F9Z Phase 1/2 [11]
⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas
Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Fusion protein Bcr-Abl T315I mutant (Bcr-Abl T315I) TTIV39N BCR_HUMAN-ABL1_HUMAN Inhibitor [2]
Proto-oncogene c-Src (SRC) TT6PKBN SRC_HUMAN Inhibitor [1]

References

1 9-(Arenethenyl)purines as dual Src/Abl kinase inhibitors targeting the inactive conformation: design, synthesis, and biological evaluation. J Med Chem. 2009 Aug 13;52(15):4743-56.
2 Discovery of 3-[2-(imidazo[1,2-b]pyridazin-3-yl)ethynyl]-4-methyl-N-{4-[(4-methylpiperazin-1-yl)methyl]-3-(trifluoromethyl)phenyl}benzamide (AP2453... J Med Chem. 2010 Jun 24;53(12):4701-19.
3 Bcr-Abl tyrosine kinase inhibitors: a patent review.Expert Opin Ther Pat. 2015 Apr;25(4):397-412.
4 A comparison of physicochemical property profiles of marketed oral drugs and orally bioavailable anti-cancer protein kinase inhibitors in clinical development. Curr Top Med Chem. 2007;7(14):1408-22.
5 Synthesis and Src kinase inhibitory activity of a series of 4-[(2,4-dichloro-5-methoxyphenyl)amino]-7-furyl-3-quinolinecarbonitriles. J Med Chem. 2006 Dec 28;49(26):7868-76.
6 In vivo antitumor activity of herbimycin A, a tyrosine kinase inhibitor, targeted against BCR/ABL oncoprotein in mice bearing BCR/ABL-transfected cells. Leuk Res. 1994 Nov;18(11):867-73.
7 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
8 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
9 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
10 Novel dual Src/Abl inhibitors for hematologic and solid malignancies.Expert Opin Investig Drugs.2010 Aug;19(8):931-45.
11 Clinical pipeline report, company report or official report of Turning Point Therapeutics.